The nation of Zimbabwe has turned down a significant American health deal worth 367 million US dollars (£272m) over five years over Washington's request for confidential biological samples.
This move was revealed after a official document from December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the arrangement was "skewed".
An official spokesperson later clarified that the US was seeking biological samples for research and commercial purposes while was unwilling to share the resulting advantages from future vaccines.
"We must now begin the challenging and unfortunate task of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had donated over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged further negotiations to secure a deal agreeable to all parties so the nation's critical HIV programme can continue.
Broader Background
This development comes after a comparable case in neighbouring Kenya, where a high court halted a similar deal with the US following legal challenges were raised about the security of Kenyans' medical information.
Since returning to the presidency recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had managed aid for the American government, but Trump claimed its spending was "wasteful" and his administration was pursuing government-to-government deals to boost transparency and accountability.
As per reports, Sixteen nations in Africa have to date signed similar agreements, representing over $18.3bn of fresh investment.
Specifics of the Declined Deal
This assistance for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration could have provided extraordinary benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy through US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Our nation was requested to surrender its genetic material and health information for a long time, without any corresponding promise of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that shared data," Mangwana explained.
"Effectively, our nation would supply the raw materials for scientific discovery with no certainty that the resulting innovations would be accessible to our citizens if a future disease outbreak emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were disrupting structures already set up through the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to deal with potential pandemics.
"This framework is designed to guarantee that when a nation contributes its information, the benefits – including medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to create them."
These objections over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We are open to ongoing dialogue with our US partners on how subsequent co-operation might be designed in a manner that honours the sovereignty and interests of each country."
Health Experts Reaction
Medical experts said it recognised the official position, but urged that negotiations must proceed since a large portion of the country's Aids initiatives were funded by foreign aid.
"Where technical issues arise, such as those involving information security or agreement terms, these can often be addressed via technical clarification and mutually agreed protections," it commented.
The situation highlights the complex tensions between receiving much-needed foreign assistance and safeguarding local interests in an ever more data-driven world.